Is this a Prime Time To acquire ChromaDex Corporation (CDXC) stock

In other words, the price has increased by $0.0000 from its previous closing price. On the day, 150850 shares were traded. CDXC stock price reached its highest trading level at $1.7400 during the session, while it also had its lowest trading level at $1.6650.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored

Ratios:

Our goal is to gain a better understanding of CDXC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.30 and its Current Ratio is at 2.30. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On August 11, 2022, B. Riley Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $2.40.

On March 08, 2022, ROTH Capital started tracking the stock assigning a Buy rating and target price of $7.ROTH Capital initiated its Buy rating on March 08, 2022, with a $7 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 30 when Fried Robert N bought 80,000 shares for $1.25 per share. The transaction valued at 100,000 led to the insider holds 972,314 shares of the business.

Chau Hoi Shuen Solina Holly bought 960,000 shares of CDXC for $1,200,000 on Sep 30. The 10% Owner now owns 7,885,641 shares after completing the transaction at $1.25 per share. On Jun 16, another insider, Chau Hoi Shuen Solina Holly, who serves as the 10% Owner of the company, bought 60,037 shares for $1.66 each. As a result, the insider paid 99,878 and bolstered with 6,925,641 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 1.92 while its Price-to-Book (P/B) ratio in mrq is 5.48.

Stock Price History:

Over the past 52 weeks, CDXC has reached a high of $5.10, while it has fallen to a 52-week low of $1.15. The 50-Day Moving Average of the stock is 1.5118, while the 200-Day Moving Average is calculated to be 1.8815.

Shares Statistics:

The stock has traded on average 270.63K shares per day over the past 3-months and 336.49k shares per day over the last 10 days, according to various share statistics. A total of 68.34M shares are outstanding, with a floating share count of 40.78M. Insiders hold about 12.00% of the company’s shares, while institutions hold 16.70% stake in the company. Shares short for CDXC as of Oct 13, 2022 were 2.02M with a Short Ratio of 2.05M, compared to 2.16M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 2.95% and a Short% of Float of 3.35%.

Earnings Estimates

Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.06 for the current quarter, with a high estimate of -$0.04 and a low estimate of -$0.08, while EPS last year was -$0.13. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.02 and low estimates of -$0.05.

Analysts are recommending an EPS of between -$0.28 and -$0.33 for the fiscal current year, implying an average EPS of -$0.31. EPS for the following year is -$0.14, with 6 analysts recommending between $0.06 and -$0.24.

Revenue Estimates

6 analysts predict $18.69M in revenue for the current quarter. It ranges from a high estimate of $19M to a low estimate of $18.46M. As of the current estimate, ChromaDex Corporation’s year-ago sales were $17.31M, an estimated increase of 8.00% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $20.04M, an increase of 12.80% over than the figure of $8.00% in the same quarter last year. There is a high estimate of $21M for the next quarter, whereas the lowest estimate is $19.69M.

A total of 6 analysts have provided revenue estimates for CDXC’s current fiscal year. The highest revenue estimate was $73.99M, while the lowest revenue estimate was $72.28M, resulting in an average revenue estimate of $72.7M. In the same quarter a year ago, actual revenue was $67.45M, up 7.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $88.45M in the next fiscal year. The high estimate is $100M and the low estimate is $84.04M. The average revenue growth estimate for next year is up 21.70% from the average revenue estimate for this year.